National Heart, Lung and Blood Institute, National Institutes of Health , Bethesda, MD, USA.
Blood. 2011 Jan 13;117(2):563-74. doi: 10.1182/blood-2010-05-284984. Epub 2010 Oct 12.
Chronic lymphocytic leukemia (CLL), an incurable malignancy of mature B lymphocytes, involves blood, bone marrow, and secondary lymphoid organs such as the lymph nodes (LN). A role of the tissue microenvironment in the pathogenesis of CLL is hypothesized based on in vitro observations, but its contribution in vivo remains ill-defined. To elucidate the effects of tumor-host interactions in vivo, we purified tumor cells from 24 treatment-naive patients. Samples were obtained concurrently from blood, bone marrow, and/or LN and analyzed by gene expression profiling. We identified the LN as a key site in CLL pathogenesis. CLL cells in the LN showed up-regulation of gene signatures, indicating B-cell receptor (BCR) and nuclear factor-κB activation. Consistent with antigen-dependent BCR signaling and canonical nuclear factor-κB activation, we detected phosphorylation of SYK and IκBα, respectively. Expression of BCR target genes was stronger in clinically more aggressive CLL, indicating more effective BCR signaling in this subtype in vivo. Tumor proliferation, quantified by the expression of the E2F and c-MYC target genes and verified with Ki67 staining by flow cytometry, was highest in the LN and was correlated with clinical disease progression. These data identify the disruption of tumor microenvironment interactions and the inhibition of BCR signaling as promising therapeutic strategies in CLL. This study is registered at http://clinicaltrials.gov as NCT00019370.
慢性淋巴细胞白血病(CLL)是一种不可治愈的成熟 B 淋巴细胞恶性肿瘤,涉及血液、骨髓和次级淋巴器官,如淋巴结(LN)。基于体外观察,假设组织微环境在 CLL 的发病机制中起作用,但在体内的贡献仍未明确。为了阐明肿瘤-宿主相互作用在体内的影响,我们从 24 名未经治疗的患者中纯化了肿瘤细胞。同时从血液、骨髓和/或 LN 获得样本,并通过基因表达谱进行分析。我们确定 LN 是 CLL 发病机制中的关键部位。LN 中的 CLL 细胞表现出 B 细胞受体(BCR)和核因子-κB 激活的基因特征上调。与抗原依赖性 BCR 信号和经典核因子-κB 激活一致,我们分别检测到 SYK 和 IκBα的磷酸化。BCR 靶基因的表达在临床上侵袭性更强的 CLL 中更强,表明在体内这种亚型中 BCR 信号更有效。通过流式细胞术 Ki67 染色验证的 E2F 和 c-MYC 靶基因的表达来定量肿瘤增殖,在 LN 中最高,并与临床疾病进展相关。这些数据表明,破坏肿瘤微环境相互作用和抑制 BCR 信号是 CLL 有前途的治疗策略。本研究在 http://clinicaltrials.gov 上注册为 NCT00019370。